This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) The topic of this article may not meet Wikipedia's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.Find sources: "Brighton Collaboration" – news · newspapers · books · scholar · JSTOR (December 2017) (Learn how and when to remove this template message) This article may need to be rewritten to comply with Wikipedia's quality standards. You can help. The talk page may contain suggestions. (September 2021) (Learn how and when to remove this template message)
The Brighton Collaboration
Formation2000 (2000)
TypeNPO
PurposeSafest, effective vaccines based on rigorous science
To enhance the science of vaccine research by providing standardized, validated, and objective methods for continuous monitoring of safety profiles and by assessing benefit-risk ratios. These methods are, in turn, recognized and recommended for use by international regulatory and public health agencies.[1]
HeadquartersBasel, Switzerland
Region served
Worldwide
Official language
English
LeaderJan Bonhoeffer, president
Parent organization
Task Force for Global Health
AffiliationsCoalition for Epidemic Preparedness Innovations
Websitebrightoncollaboration.us

The Brighton Collaboration (BC) is a non-profit global vaccine safety research network based in Basel, Switzerland. It is named after the city in England where the idea was first formulated.[2]

History

The Brighton Collaboration was launched in 2000, although the idea of the collaboration started one year earlier, following a presentation by Bob Chen at an international scientific vaccine conference in Brighton. In his talk, he stressed the need to improve vaccine safety monitoring by developing internationally accepted standards.[3]

Organization

The Brighton Collaboration is a program of the Task Force for Global Health, a 501(c)(3) non-profit organization. It is primarily funded by the Coalition for Epidemic Preparedness Innovations (CEPI), and has received funding from a variety of scientific and public health organizations since its inception.[4]

Non-funding partners of the Collaboration include the Council for International Organizations of Medical Sciences, European Medicines Agency, Food and Drug Administration and the World Health Organization.[4]

References

  1. ^ "EVI and Brighton Collaboration Foundation (BCF) sign Memorandum of Understanding (MoU)". Archived from the original on 2011-10-31. Retrieved 2012-07-17.
  2. ^ Kohl, Katrin S.; Bonhoeffer, Jan; Braun, M. Miles; Chen, Robert T.; Duclos, Philippe; Heijbel, Harald; Heininger, Ulrich; Loupi, Elisabeth; Marcy, S. Michael (February 2005), Henriksen, Kerm; Battles, James B.; Marks, Eric S.; Lewin, David I. (eds.), "The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization", Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology), Advances in Patient Safety, Rockville (MD): Agency for Healthcare Research and Quality (US), PMID 21249832, archived from the original on 2022-12-12, retrieved 2023-07-04
  3. ^ Chen RT (1999). "Vaccine risks: real, perceived and unknown". Vaccine. 17 (Suppl 3): S41-6. doi:10.1016/s0264-410x(99)00292-3. PMID 10559533.
  4. ^ a b "Our Partners". Brighton Collaboration. Archived from the original on 2023-07-04. Retrieved 2023-07-04.


Categories